Abstract 300P
Background
Cervical cancer is the leading cause of death among gynecological cancers and ranks seventh among all types of cancer affecting women in Vietnam, with about 15.7% of cases occurring in women under 40 years old. Post-operative radiation therapy can cause ovarian dysfunction and related complications even in patients who had the ovaries transposed. This study aims to evaluate the extent of radiation exposure to the transposed ovaries and its impact on ovarian function in cervical cancer patients at the Ho Chi Minh City Oncology Hospital, who have undergone ovary transposition and received adjuvant radiation therapy.
Methods
We studied retrospectively radiation dosages and ovarian functions in cervix cancer patients who had ovarian transposition at our hospital from Jan 2020 to Dec 2021. We included patients under 45 years who completed at least 6 months of radiation therapy, and collected data on their medical records and radiotherapy planning software. Ovarian function was evaluated by FSH and estradiol levels before and after treatment. We used Epidata and Stata software to analyze the data and tested correlations using t-test pairing, Fisher test, and Spearman correlation.
Results
A total of 22 patients were included in the study. The mean radiation dose to the ovaries was positively correlated with PTV, ovarian position, stage and radiation technique. Of the 15 patients whose ovarian function was investigated after radiotherapy, 5 patients (33.33%) preserved ovarian function. The function preserved groups had lower ovarian radiation dosage. Table: 300P
Mean ovarian dosage (Gy) +/- SD (n) | Range | p | |
StageIB2IB3IIA1IIIC1p | 6,14 +/- 6,5 (16)14,26 +/- 12,14 (12)11,21 +/- 10,65 (4)15,86 +/- 15,29 (8) | 0,854-190.946-35,8670,963-21,130,885-45,562 | p=0,21 |
Ovarian position:Inside pelvis outside pelvis | 20,63 +/- 11,92 (13)6,4 +/- 7,88 (27) | 3,532-42,560,85-29,57 | 0,008 |
FunctionPreservedNot preserved | 1,29 +/- 2,13 (5)20,54 +/- 11,23 (10) | 1,09 -3,24,231-42,562 | 0,001 |
Technique3D CRTIMRT | 6,46 +/- 9,89 (27)19,45 +/- 9,03 (13) | 42,58 -0,8535,87 -5,29 | 0,0001 |
Conclusions
Transposed ovary location and mean ovarian dose are important factors in determining ovarian function outcomes. 3D CRT was better than IMRT, possibly due to scatter doses and inadequate ovarian dose constraints during radiation therapy planning. Increasing sample size and establishing a consistent practice protocol could enhance the validity of this study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ho Chi Minh City University of Medicine and Pharmacy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract